New York, June 4, 2026, 06:01 EDT
- MetaVia was indicated down 1.1% at $2.65 in pre-market trading after closing at $2.68 on Wednesday.
- The stock has fallen about 20% from its May 27 close, when the company released higher-dose DA-1726 data.
- Investors next face ADA poster presentations on June 7 and a June 8 shareholder vote that includes a reverse-split proposal.
MetaVia Inc. shares slipped before the bell on Thursday, extending a sharp pullback from last week’s rally as investors weighed early obesity-drug data against financing and listing risks at the small biotech.
The Nasdaq-listed stock was quoted at $2.65 in pre-market trade, down 1.1%, after a $2.68 close on Wednesday. It has now retreated from $3.34 on May 27, the day MetaVia presented new Phase 1 data for DA-1726 at the European Association for the Study of the Liver Congress.
That matters now because MetaVia’s market value is tied heavily to DA-1726, a once-weekly GLP-1/glucagon receptor drug candidate. GLP-1 drugs act on a gut-hormone pathway used in weight-loss medicines to curb appetite; glucagon receptor activity may raise energy use, though it also puts more focus on heart-rate and other safety markers.
MetaVia said the 48 mg cohort in its early human study showed mean body-weight reduction of 9.1% by Day 54 and a 9.8 cm cut in waist circumference, with no serious adverse events or treatment-related discontinuations. Phase 1 means the drug is still in an early safety and dosing stage, far from approval.
“These late-breaking Phase 1 findings” reinforced DA-1726’s metabolic profile, Chief Executive Hyung Heon Kim said in the company’s release. He said the drug showed “progressive weight loss” while keeping favorable tolerability, even without dose titration, or gradual dose increases. PR Newswire
The next near-term test comes at the American Diabetes Association’s Scientific Sessions in New Orleans, where MetaVia is due to present three late-breaking posters on June 7. One covers DA-1726 higher-dose Phase 1 results; two others cover vanoglipel, its GPR119 agonist being studied for metabolic dysfunction-associated steatohepatitis, or MASH, a serious fatty-liver disease tied to metabolic illness.
In a sponsored Zacks Small-Cap Research note dated May 28, David Bautz wrote that the data were “very encouraging” for weight loss and potential liver-health benefits, with “no obvious cardiac safety concerns.” Zacks kept a $30 valuation in that report, while also marking the stock as high risk.
The competitive bar is high. MetaVia’s own materials compare DA-1726 in pre-clinical mouse models with semaglutide, sold as Wegovy, tirzepatide, sold as Zepbound, and survodutide, another GLP-1/glucagon drug candidate. Those are useful reference points, but animal data do not settle whether DA-1726 can match or beat larger rivals in later human trials.
The company remains pre-commercial. MetaVia reported a first-quarter net loss of $3.8 million, or 79 cents a share, and $13.7 million in cash and cash equivalents as of March 31. It said that cash should fund operations into the fourth quarter of 2026, the same period when it expects data from its 16-week Part 3 titration study of DA-1726.
But the trade is fragile. The 48 mg data came from a small early cohort, and longer dosing may show different safety, tolerability or weight-loss patterns. MetaVia also lists the need to raise capital, complete trials on time and get results consistent with prior work among its risks.
There is another overhang. At its virtual annual meeting on June 8, shareholders are being asked to approve authority for a reverse split at a ratio from 1-for-5 to 1-for-22, with the board saying the main intent is to lift the share price and help maintain Nasdaq listing standards. The filing also warns a reverse split may not deliver those benefits and could hurt liquidity.
For now, traders have a narrow window to price the next catalysts: ADA posters this weekend, the reverse-split vote on Monday and, farther out, fourth-quarter DA-1726 data that will matter more than the last few cents in pre-market trade.
